Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Betaferon

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

- PMLiVE

Novartis sells off part of Sandoz portfolio

Swiss pharma giant will retain biosimilars

- PMLiVE

NICE U-turn on Crystiva for rare bone disease

Watchdog to back the drug to treat young people with XLH

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

Drug increased PFS by 2.6 months compared to Pfizer’s Sutent

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

- PMLiVE

Shock as NICE turns down Biogen’s SMA therapy

UK’s cost effectiveness watchdog says the drug’s long-term benefits are unclear

- PMLiVE

Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland

The latest from pharma, biotech and healthcare

- PMLiVE

After Cohen payment scandal, Novartis unveils new ethics chief

New 'risk and compliance' leader has increased powers

- PMLiVE

FDA gives breakthrough status to Xolair for food allergies

Food allergies could open up big new market for biologic

- PMLiVE

Promising more appraisal capacity, NICE revives industry fee idea

Rising workload and shrinking budget making charges inevitable

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links